Albinterferon alfa-2b
Albinterferon alfa-2b is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
383 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 28 | 31 | 26 | 14 | 97 |
| Hepatitis c | D006526 | B19.2 | 6 | 18 | 21 | 13 | 6 | 58 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 12 | 14 | 6 | 2 | 3 | 33 |
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 5 | 9 | 11 | 5 | 7 | 32 |
| Neoplasms | D009369 | C80 | 8 | 5 | — | 1 | — | 13 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 4 | 1 | 3 | 8 |
| Hepacivirus | D016174 | — | 4 | 3 | 1 | 1 | 8 | ||
| Hepatitis b | D006509 | — | 2 | 2 | 1 | 3 | 8 | ||
| Hiv | D006678 | O98.7 | 1 | 1 | — | 2 | — | 4 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 2 | — | 1 | 1 | 4 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 13 | 14 | 9 | — | 1 | 35 | ||
| Renal cell carcinoma | D002292 | 3 | 12 | 3 | — | 1 | 16 | ||
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 6 | 5 | — | — | 10 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 5 | 1 | — | — | 7 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | 2 | — | 1 | 5 |
| Polycythemia vera | D011087 | D45 | — | 1 | 3 | — | — | 4 | |
| Covid-19 | D000086382 | U07.1 | 2 | 3 | 1 | — | — | 3 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | 2 | — | — | 3 | |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | — | — | 3 | |
| Recurrence | D012008 | 1 | 3 | 2 | — | — | 3 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 3 | — | — | — | 5 |
| Kaposi sarcoma | D012514 | C46 | 3 | 2 | — | — | — | 5 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 4 | — | — | — | 4 |
| Leukemia | D007938 | C95 | 2 | 1 | — | — | 1 | 3 | |
| Prostatic neoplasms | D011471 | C61 | — | 2 | — | — | — | 2 | |
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 | ||
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | 1 | 2 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | — | — | — | 2 | |
| Carcinoma | D002277 | C80.0 | — | 1 | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | 1 | 4 | ||
| Triple negative breast neoplasms | D064726 | 2 | — | — | — | — | 2 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous substance abuse | D015819 | — | — | — | — | 1 | 1 | ||
| Lipodystrophy | D008060 | E88.1 | — | — | — | — | 1 | 1 | |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | — | — | 1 | 1 | |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Ascites | D001201 | HP_0001541 | R18 | — | — | — | — | 1 | 1 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALBINTERFERON ALFA-2B |
| INN | albinterferon alfa-2b |
| Description | Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin. Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 472960-22-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107842 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB05396 |
| UNII ID | 4DVS4AG4DF (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 0 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more